Moores Cancer Center at UC San Diego Health is among the few clinical trial sites in the U.S. for the Pancreatic Cancer Action Network’s newly created Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.
Stand Up to Cancer (SU2C) and Mirati Therapeutics said on Monday that Mirati has awarded $4 million to SU2C to advance treatment for KRAS-mutant cancers.
The research will focus on cancer types with unmet medical needs, and the application of tumor-agnostic strategies and molecular testing to address those needs.
A new team of pioneering pancreatic cancer researchers has been formed to predict which treatments might work best for individual pancreatic cancer patients based on the molecular traits of tumors.
A team of researchers from four New York institutions have received $6 million from Stand Up to Cancer to address the low participation of Black, Indigenous and People of Color in cancer clinical trials.
The Cinequest Film and Creativity Festival and Stand Up To Cancer (SU2C) have announced the launch of their inaugural Laura Ziskin Visionary Award.
Stand Up To Cancer® (SU2C) today announced funding for its first team of researchers dedicated to health equity in cancer research.
Researchers are teaming up on a $6 million initiative to diversify clinical trials for cancer research and treatment.
Jamie Foxx has joined Stand Up To Cancer (SU2C) and Exact Sciences for a new public service announcement to raise awareness about early detection and prevention and focuses on reaching underrepresented communities.
